The Lynx Group

Breast Cancer

“We are confident that this will mark the first steps toward a reduction of the duration of trastuzumab in many women with HER2-positive breast cancer,” says Helena M. Earl, MBBS, PhD, FRCP.
Read Article


Breast cancer affects more women than any other type of cancer, and represents 15% of all new cancer cases in the United States. A total of 252,710 new breast cancer cases were estimated to be diagnosed in 2017, and more than 40,600 deaths. The prognosis worsens for patients with locally advanced breast cancer and even more so for those with metastatic disease.
Read Article

Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 252,710 American women will be diagnosed with breast cancer and 40,610 will die from the disease in 2017. For the majority (62%) of women with breast cancer, the disease is confined to the breast, and the 5-year survival approaches 100%. However, for women with metastatic disease, the likelihood of survival at 5 years drops to 27%.
Read Article

CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer
Dr Matthew Goetz addresses the prospect of utilizing CDK4/6 inhibitors to treat patients with HER2+ metastatic breast cancer, stating early data indicate that CDK4/6 inhibitors may have some antitumor activity in HER2+ breast cancer.
Read Article

Questions About Treating Patients Using a CDK4/6 Inhibitor
Dr Matthew Goetz addresses common questions that arise when patients with HER-positive metastatic breast cancer have progressed on a CDK4/6 inhibitor plus an aromatase inhibitor.
Read Article

Abemaciclib, Ribociclib, or Palbociclib for HR+ Metastatic Breast Cancer?
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.
Read Article

The Use of Chemotherapy in the Metastatic Setting
Dr Matthew Goetz believes that, as more mature data come into existence, the demonstration of a survival advantage will guide more patients with metastatic breast cancer to try CDK4/6 inhibitors plus aromatase inhibitors instead of chemotherapy.
Read Article

The Mechanism of Action of CDK4/6 Inhibitors
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Read Article

HER2-Positive Breast Cancer and CDK4/6 Inhibitors
Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2-positive breast cancer.
Read Article

Page 3 of 11

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: